LONDON and PHILADELPHIA, June 2 /PRNewswire-FirstCall/ --
GlaxoSmithKline plc (NYSE: GSK) announced today the successful completion
of the tender offer by its wholly-owned subsidiary Fountain Acquisition
Corporation (FAC) for shares of common stock of Sirtris Pharmaceuticals,
Inc. (Nasdaq: SIRT).
The depositary for the offer has advised GSK and FAC that stockholders
of Sirtris have now tendered a total of approximately 28,931,756 Sirtris
shares (including shares tendered through notice of guaranteed delivery),
representing approximately 97% of the outstanding common stock of Sirtris.
FAC has accepted for payment all Sirtris shares tendered in the offer.
FAC's ownership of the common stock of Sirtris exceeds the 90% required
to effect a short-form merger of FAC with and into Sirtris under Delaware
law. FAC expects to effect the short-form merger later this week, without
the need for a meeting of Sirtris stockholders. In the merger, FAC will
acquire all other Sirtris shares (other than those as to which holders
properly exercise appraisal rights) at the same $22.50 per share price,
without interest and less any required withholding taxes, that was paid in
the tender offer. As a result of the merger, Sirtris will become a
wholly-owned subsidiary of GSK.
About GlaxoSmithKline plc
GlaxoSmithKline plc -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer. For company information including a copy of this announcement and
details of the company's updated product development pipeline, visit GSK at
Sirtris Pharmaceuticals, Inc. is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with ageing,
including metabolic diseases such as Type 2 Diabetes. Sirtris' drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction by activation of sirtuins, a recently discovered class
of enzymes that Sirtris believes control the ageing process. Sirtris'
headquarters are in Cambridge, Massachusetts.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities
Litigation Reform Act of 1995, the company cautions investors that any
forward-looking statements or projections made by the company, including
those made in this Announcement, are subject to risks and uncertainties
that may cause actual results to differ materially from those projected.
Factors that may cause or contribute to such differences include the risk
that the conditions to the closing of the tender offer or the merger set
forth in the merger agreement will not be satisfied; changes in GSK's and
Sirtris' businesses during the period between now and the closing;
obtaining regulatory approvals if required for the transaction; the
successful integration of Sirtris into GSK's business subsequent to the
closing of the acquisition; the ability to retain key management and
technical personnel of Sirtris; and other factors described in GSK's Annual
Report 2007 under 'Risk Factors' in the 'Operating and Financial Review and
Prospects'. GSK is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements whether as a
result of new information, future events or otherwise.
SOURCE GlaxoSmithKline plc